Dec 1, 2001 By:
Jill Wechsler Pharmaceutical Executive
Washington, DC-The run on Cipro following October's anthrax scare was a bonanza for pharmacy websites, but it stirred the
wrath of both FDA and the medical establishment. In response to escalating ciprofloxacin promotion over the internet, FDA
sent cyber letters to 11 websites for offering US consumers products that may not be approved for sale in the United States,
warning that US Customs might detain shipments. The agency also took more stringent action against five previously warned
foreign vendors.
Pharmacists also were quick to alert the public to the risk of purchasing antibiotics online, because the products could be
counterfeit, contaminated, expired, or ineffective. Pharmacists generally oppose internet and mail-order sales of medicines,
especially from overseas vendors.
And those operators' assertions that they will fill a prescription only after an online "consultation" with a doctor have
antagonized the medical community. The North Carolina Medical Board brought charges against a physician for writing Cipro
prescriptions with only a "virtual" check-up, performed through VirtualMedicalGroup, which is linked to the state's MedicalWeb.com.
Although the North Carolina medical board stated that online prescribing is unprofessional and "inappropriate," it is not
illegal in most states. VirtualMedicalGroup says it obtains Cipro from a US wholesaler, which may keep it out of trouble with
FDA.
Before the Cipro shortage, online pharmacy operations had moved out of the limelight, according to Anne Maher, formerly with
the Federal Trade Commission. Last year's dotcom crash and the demise of some big pharmacy websites further depleted the relatively
low number of consumers using those services, and a regulatory crackdown by FTC and FDA also hurt the budding field. FTC continues
to watch online pharmacy activities, but it probably spends more energy keeping track of how marketers provide product information
to consumers through their websites.
Jill Wechsler is the Washington Editor for Pharmaceutical Executive and writes about federal government policies and programs that affect the pharmaceutical industry. Her monthly Washington Report discusses legislative proposals, FDA initiatives and actions by other government agencies, including Medicare pharmacy benefit proposals, federal
investigations related to pharmaceutical company marketing, debate over DTC advertising, generic drug competition, over-the-counter initiatives, among
other topics. She has written for PE for more than ten years and also covers Washington for other Advanstar publications, including Pharmaceutical Technology, Applied Clinical Trials, BioPharm, Managed Healthcare Executive and Formulary. Prior to that she reported on
government policies and a wide range of topics for business and consumer publications.
Articles by Jill Wechsler